Elisabet Borsheim
Concepts (335)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Burns | 14 | 2022 | 165 | 4.020 |
Why?
| Muscle, Skeletal | 24 | 2022 | 784 | 3.750 |
Why?
| Insulin Resistance | 12 | 2022 | 268 | 3.450 |
Why?
| Exercise | 20 | 2025 | 516 | 3.260 |
Why?
| Muscle Proteins | 14 | 2022 | 320 | 2.750 |
Why?
| Adiposity | 6 | 2024 | 137 | 2.070 |
Why?
| Insulin | 16 | 2022 | 467 | 1.860 |
Why?
| Body Mass Index | 11 | 2025 | 677 | 1.780 |
Why?
| Mitochondria, Muscle | 5 | 2019 | 37 | 1.760 |
Why?
| Oxygen Consumption | 9 | 2021 | 190 | 1.670 |
Why?
| Body Composition | 7 | 2025 | 327 | 1.660 |
Why?
| Pregnant Women | 4 | 2022 | 72 | 1.600 |
Why?
| Diabetes, Gestational | 2 | 2022 | 52 | 1.400 |
Why?
| Blood Glucose | 10 | 2022 | 446 | 1.280 |
Why?
| Amino Acids | 8 | 2022 | 373 | 1.270 |
Why?
| Dietary Proteins | 3 | 2021 | 252 | 1.270 |
Why?
| Energy Metabolism | 11 | 2022 | 286 | 1.230 |
Why?
| Phenylalanine | 7 | 2022 | 134 | 1.170 |
Why?
| Sulfoxides | 3 | 2025 | 21 | 1.130 |
Why?
| Isothiocyanates | 3 | 2025 | 19 | 1.130 |
Why?
| Physical Fitness | 2 | 2025 | 60 | 1.110 |
Why?
| Obesity | 12 | 2024 | 1121 | 1.100 |
Why?
| Proteins | 2 | 2025 | 339 | 1.060 |
Why?
| Alanine | 2 | 2025 | 43 | 1.050 |
Why?
| Amino Acids, Essential | 5 | 2008 | 133 | 1.050 |
Why?
| Humans | 73 | 2025 | 50503 | 1.040 |
Why?
| Female | 49 | 2025 | 27081 | 1.040 |
Why?
| Pregnancy | 15 | 2024 | 2452 | 1.030 |
Why?
| Triglycerides | 8 | 2022 | 160 | 1.010 |
Why?
| Child | 20 | 2025 | 6906 | 1.000 |
Why?
| Resistance Training | 3 | 2022 | 100 | 0.990 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2025 | 68 | 0.950 |
Why?
| Postural Balance | 1 | 2025 | 58 | 0.910 |
Why?
| Male | 50 | 2025 | 25907 | 0.910 |
Why?
| Child, Preschool | 15 | 2024 | 3942 | 0.910 |
Why?
| Leptin | 2 | 2022 | 143 | 0.910 |
Why?
| Adipose Tissue | 4 | 2019 | 192 | 0.880 |
Why?
| NF-E2-Related Factor 2 | 2 | 2021 | 40 | 0.880 |
Why?
| Oxidative Stress | 4 | 2025 | 772 | 0.880 |
Why?
| Eating | 2 | 2021 | 158 | 0.860 |
Why?
| Amino Acids, Branched-Chain | 2 | 2021 | 42 | 0.840 |
Why?
| Maternal Nutritional Physiological Phenomena | 2 | 2020 | 55 | 0.790 |
Why?
| Threonine | 1 | 2022 | 15 | 0.780 |
Why?
| Zinc | 1 | 2022 | 52 | 0.770 |
Why?
| Liver | 6 | 2023 | 1132 | 0.760 |
Why?
| Parents | 2 | 2022 | 318 | 0.750 |
Why?
| Breast Feeding | 2 | 2022 | 189 | 0.730 |
Why?
| Nutrition Policy | 1 | 2021 | 39 | 0.720 |
Why?
| Nutritional Requirements | 1 | 2021 | 68 | 0.710 |
Why?
| DNA Methylation | 2 | 2022 | 550 | 0.700 |
Why?
| Adrenergic beta-Antagonists | 3 | 2014 | 108 | 0.700 |
Why?
| Diabetes Mellitus, Type 2 | 3 | 2025 | 519 | 0.670 |
Why?
| Health Behavior | 1 | 2022 | 253 | 0.660 |
Why?
| Indocyanine Green | 2 | 2019 | 34 | 0.650 |
Why?
| Blood Pressure | 2 | 2021 | 531 | 0.650 |
Why?
| Blood Cells | 1 | 2019 | 47 | 0.640 |
Why?
| Adult | 28 | 2024 | 13577 | 0.630 |
Why?
| Muscle Fibers, Skeletal | 1 | 2019 | 62 | 0.610 |
Why?
| Adipose Tissue, Brown | 5 | 2016 | 40 | 0.590 |
Why?
| Arginine | 4 | 2022 | 187 | 0.560 |
Why?
| Leucine | 6 | 2021 | 117 | 0.550 |
Why?
| Weight Gain | 4 | 2022 | 237 | 0.540 |
Why?
| Muscle Strength | 3 | 2025 | 127 | 0.520 |
Why?
| Hypoglycemic Agents | 2 | 2014 | 173 | 0.500 |
Why?
| Autonomic Nervous System | 1 | 2016 | 58 | 0.500 |
Why?
| Adolescent | 14 | 2023 | 6443 | 0.490 |
Why?
| Electron Transport Complex II | 1 | 2015 | 7 | 0.490 |
Why?
| Dietary Supplements | 8 | 2025 | 449 | 0.490 |
Why?
| Electron Transport Complex I | 1 | 2015 | 23 | 0.490 |
Why?
| Oxidative Phosphorylation | 1 | 2015 | 41 | 0.480 |
Why?
| Oxidation-Reduction | 6 | 2021 | 316 | 0.480 |
Why?
| Metabolic Diseases | 3 | 2025 | 44 | 0.460 |
Why?
| Androgens | 1 | 2014 | 70 | 0.460 |
Why?
| Anabolic Agents | 1 | 2014 | 39 | 0.460 |
Why?
| Down-Regulation | 1 | 2015 | 340 | 0.440 |
Why?
| Muscles | 1 | 2014 | 104 | 0.440 |
Why?
| Dietary Carbohydrates | 2 | 2004 | 91 | 0.430 |
Why?
| Diphosphonates | 1 | 2014 | 90 | 0.430 |
Why?
| Physical Exertion | 3 | 1998 | 48 | 0.410 |
Why?
| Cohort Studies | 5 | 2021 | 1452 | 0.410 |
Why?
| Time Factors | 11 | 2020 | 2935 | 0.410 |
Why?
| Fatty Acids, Nonesterified | 4 | 2020 | 39 | 0.400 |
Why?
| Aging | 3 | 2015 | 693 | 0.400 |
Why?
| Animals | 15 | 2025 | 13124 | 0.380 |
Why?
| Case-Control Studies | 5 | 2021 | 1156 | 0.380 |
Why?
| Kinetics | 5 | 2025 | 623 | 0.370 |
Why?
| Deuterium | 4 | 2025 | 45 | 0.360 |
Why?
| Adiponectin | 2 | 2021 | 46 | 0.360 |
Why?
| Reproducibility of Results | 4 | 2025 | 1197 | 0.350 |
Why?
| Homeostasis | 3 | 2021 | 204 | 0.350 |
Why?
| Nitrogen Isotopes | 3 | 2022 | 38 | 0.330 |
Why?
| Lipid Metabolism | 3 | 2016 | 175 | 0.330 |
Why?
| Glucose | 3 | 2023 | 341 | 0.330 |
Why?
| Glucose Intolerance | 3 | 2020 | 27 | 0.330 |
Why?
| Absorptiometry, Photon | 3 | 2025 | 155 | 0.330 |
Why?
| Receptors, Adrenergic, beta | 2 | 2000 | 42 | 0.320 |
Why?
| Anthropometry | 3 | 2025 | 95 | 0.320 |
Why?
| Longitudinal Studies | 4 | 2024 | 735 | 0.310 |
Why?
| Hypertriglyceridemia | 1 | 2008 | 16 | 0.310 |
Why?
| MicroRNAs | 2 | 2022 | 344 | 0.310 |
Why?
| Fatty Acids | 3 | 2004 | 144 | 0.300 |
Why?
| Palmitic Acid | 2 | 2006 | 22 | 0.280 |
Why?
| Young Adult | 8 | 2024 | 4102 | 0.280 |
Why?
| Oleic Acid | 1 | 2006 | 5 | 0.270 |
Why?
| Nitrogen | 2 | 2021 | 70 | 0.260 |
Why?
| Lipids | 3 | 2023 | 152 | 0.260 |
Why?
| Carnitine | 2 | 2022 | 63 | 0.250 |
Why?
| Protein Biosynthesis | 4 | 2017 | 232 | 0.250 |
Why?
| Brain Injuries | 1 | 2007 | 159 | 0.240 |
Why?
| Deuterium Oxide | 1 | 2025 | 9 | 0.240 |
Why?
| Infant | 4 | 2021 | 3628 | 0.240 |
Why?
| Accelerometry | 1 | 2025 | 12 | 0.240 |
Why?
| Renal Dialysis | 2 | 2005 | 171 | 0.240 |
Why?
| Adaptation, Physiological | 2 | 2014 | 93 | 0.230 |
Why?
| Weight Lifting | 1 | 2004 | 29 | 0.230 |
Why?
| Rats | 3 | 2025 | 3292 | 0.220 |
Why?
| Mitochondria | 3 | 2016 | 399 | 0.220 |
Why?
| Propranolol | 4 | 2014 | 79 | 0.220 |
Why?
| Milk Proteins | 1 | 2004 | 77 | 0.220 |
Why?
| Physical Conditioning, Animal | 1 | 2023 | 57 | 0.210 |
Why?
| Inflammation | 2 | 2025 | 610 | 0.210 |
Why?
| Isoflavones | 1 | 2023 | 89 | 0.210 |
Why?
| Palmitates | 1 | 2022 | 27 | 0.200 |
Why?
| Fatty Liver | 1 | 2023 | 130 | 0.200 |
Why?
| Lipolysis | 2 | 2012 | 11 | 0.200 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2022 | 573 | 0.190 |
Why?
| Aged | 5 | 2022 | 9741 | 0.190 |
Why?
| Isoleucine | 1 | 2021 | 26 | 0.190 |
Why?
| Leukocytes, Mononuclear | 1 | 2022 | 118 | 0.190 |
Why?
| Cattle | 1 | 2022 | 205 | 0.190 |
Why?
| Skin Aging | 1 | 2021 | 9 | 0.190 |
Why?
| Cardiovascular Diseases | 2 | 2024 | 461 | 0.190 |
Why?
| Glomerular Filtration Rate | 1 | 2021 | 119 | 0.190 |
Why?
| Alanine Transaminase | 1 | 2021 | 119 | 0.190 |
Why?
| Gestational Age | 2 | 2019 | 373 | 0.180 |
Why?
| Organ Size | 2 | 2019 | 223 | 0.180 |
Why?
| Swine | 3 | 2015 | 408 | 0.180 |
Why?
| Biopsy | 3 | 2014 | 588 | 0.180 |
Why?
| Milk, Human | 1 | 2021 | 106 | 0.180 |
Why?
| Fibroblast Growth Factors | 1 | 2020 | 45 | 0.170 |
Why?
| Maternal-Fetal Exchange | 1 | 2020 | 42 | 0.170 |
Why?
| Pregnancy Complications | 1 | 2024 | 380 | 0.170 |
Why?
| Hydrocortisone | 5 | 2020 | 110 | 0.170 |
Why?
| Meals | 1 | 2020 | 62 | 0.170 |
Why?
| Physical Endurance | 3 | 2004 | 31 | 0.170 |
Why?
| Oxidative Phosphorylation Coupling Factors | 1 | 2019 | 6 | 0.160 |
Why?
| Sarcopenia | 1 | 2020 | 95 | 0.160 |
Why?
| Cross-Sectional Studies | 1 | 2025 | 1610 | 0.160 |
Why?
| Schools | 1 | 2020 | 164 | 0.160 |
Why?
| Burn Units | 1 | 2019 | 9 | 0.160 |
Why?
| Liver Failure | 1 | 2019 | 21 | 0.160 |
Why?
| Lipoproteins, VLDL | 1 | 1999 | 9 | 0.160 |
Why?
| Models, Biological | 3 | 2019 | 716 | 0.160 |
Why?
| Epigenesis, Genetic | 1 | 2022 | 372 | 0.160 |
Why?
| Monocytes | 1 | 2019 | 127 | 0.150 |
Why?
| Adipose Tissue, White | 2 | 2016 | 34 | 0.150 |
Why?
| Feeding Behavior | 1 | 2020 | 185 | 0.150 |
Why?
| Receptors, Adrenergic | 1 | 1998 | 14 | 0.150 |
Why?
| Sympathetic Nervous System | 1 | 1998 | 19 | 0.150 |
Why?
| Exercise Therapy | 2 | 2020 | 96 | 0.150 |
Why?
| Age Factors | 2 | 2019 | 1110 | 0.150 |
Why?
| Heart Rate | 5 | 2007 | 307 | 0.150 |
Why?
| Hepatocytes | 1 | 2019 | 178 | 0.150 |
Why?
| Cold Temperature | 2 | 2016 | 44 | 0.150 |
Why?
| Arkansas | 2 | 2020 | 1985 | 0.150 |
Why?
| Ion Channels | 2 | 2015 | 74 | 0.140 |
Why?
| Mitochondrial Proteins | 2 | 2015 | 88 | 0.140 |
Why?
| Risk Factors | 3 | 2024 | 3724 | 0.140 |
Why?
| Urea | 2 | 2010 | 81 | 0.130 |
Why?
| Blood Platelets | 1 | 2019 | 251 | 0.130 |
Why?
| Carbon Isotopes | 4 | 2005 | 70 | 0.130 |
Why?
| Patient Discharge | 1 | 2019 | 321 | 0.130 |
Why?
| Thermogenesis | 2 | 2014 | 24 | 0.130 |
Why?
| Carbohydrate Metabolism | 1 | 2016 | 26 | 0.130 |
Why?
| Hypertension | 1 | 2021 | 544 | 0.130 |
Why?
| Human Growth Hormone | 2 | 2014 | 50 | 0.130 |
Why?
| Treatment Outcome | 3 | 2014 | 5283 | 0.130 |
Why?
| Proton Ionophores | 1 | 2015 | 3 | 0.120 |
Why?
| Uncoupling Agents | 1 | 2015 | 5 | 0.120 |
Why?
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 2015 | 5 | 0.120 |
Why?
| Oligomycins | 1 | 2015 | 7 | 0.120 |
Why?
| Myofibrils | 1 | 2015 | 20 | 0.120 |
Why?
| Infusions, Intravenous | 2 | 2013 | 213 | 0.120 |
Why?
| Hyperinsulinism | 1 | 2015 | 27 | 0.120 |
Why?
| Ethanol | 1 | 1998 | 336 | 0.120 |
Why?
| Nutritional Support | 1 | 2015 | 35 | 0.120 |
Why?
| Oxandrolone | 1 | 2014 | 10 | 0.120 |
Why?
| Quadriceps Muscle | 1 | 2015 | 47 | 0.120 |
Why?
| Ascorbic Acid | 1 | 2014 | 21 | 0.120 |
Why?
| Body Surface Area | 1 | 2014 | 26 | 0.120 |
Why?
| Vitamins | 1 | 2014 | 63 | 0.120 |
Why?
| Stress, Physiological | 1 | 2015 | 171 | 0.110 |
Why?
| Placebos | 1 | 2014 | 87 | 0.110 |
Why?
| Testosterone | 1 | 2014 | 145 | 0.110 |
Why?
| Predictive Value of Tests | 2 | 2015 | 930 | 0.110 |
Why?
| MAP Kinase Signaling System | 1 | 2014 | 117 | 0.110 |
Why?
| Cross-Over Studies | 3 | 2020 | 228 | 0.110 |
Why?
| Vitamin E | 1 | 2014 | 78 | 0.110 |
Why?
| Mitochondrial Diseases | 1 | 2014 | 41 | 0.110 |
Why?
| Metformin | 1 | 2014 | 65 | 0.110 |
Why?
| Area Under Curve | 2 | 2004 | 179 | 0.110 |
Why?
| Mice | 2 | 2021 | 5687 | 0.110 |
Why?
| Signal Transduction | 1 | 2020 | 1624 | 0.110 |
Why?
| Norepinephrine | 3 | 2000 | 114 | 0.110 |
Why?
| Recombinant Proteins | 1 | 2014 | 476 | 0.110 |
Why?
| Cachexia | 1 | 2013 | 25 | 0.110 |
Why?
| Muscle Strength Dynamometer | 2 | 2014 | 12 | 0.100 |
Why?
| Skin | 1 | 2015 | 388 | 0.100 |
Why?
| Fenofibrate | 1 | 2012 | 16 | 0.100 |
Why?
| PPAR alpha | 1 | 2012 | 56 | 0.100 |
Why?
| Rest | 2 | 2014 | 61 | 0.090 |
Why?
| Diet | 2 | 2024 | 568 | 0.090 |
Why?
| Hyperglycemia | 1 | 2012 | 81 | 0.090 |
Why?
| Antioxidants | 2 | 2025 | 239 | 0.090 |
Why?
| Health Status | 1 | 2013 | 299 | 0.090 |
Why?
| United States | 1 | 2021 | 4955 | 0.090 |
Why?
| Middle Aged | 4 | 2016 | 12611 | 0.090 |
Why?
| Extracellular Fluid | 2 | 2009 | 14 | 0.080 |
Why?
| Isoproterenol | 2 | 2000 | 56 | 0.080 |
Why?
| Double-Blind Method | 2 | 2017 | 708 | 0.080 |
Why?
| Hemodilution | 1 | 2009 | 7 | 0.080 |
Why?
| Cholesterol, VLDL | 1 | 2008 | 3 | 0.080 |
Why?
| Isotonic Solutions | 1 | 2009 | 17 | 0.080 |
Why?
| Regional Blood Flow | 2 | 2000 | 109 | 0.080 |
Why?
| Forearm | 1 | 2009 | 28 | 0.080 |
Why?
| Prospective Studies | 1 | 2015 | 2378 | 0.080 |
Why?
| Cholesterol | 1 | 2008 | 150 | 0.070 |
Why?
| Aged, 80 and over | 1 | 2015 | 3226 | 0.070 |
Why?
| Anesthesia, Inhalation | 1 | 2007 | 12 | 0.070 |
Why?
| Isoflurane | 1 | 2007 | 14 | 0.070 |
Why?
| Reference Values | 2 | 1998 | 307 | 0.070 |
Why?
| Anesthetics, Inhalation | 1 | 2007 | 32 | 0.070 |
Why?
| Sodium Chloride | 1 | 2007 | 55 | 0.070 |
Why?
| Gait | 1 | 2008 | 89 | 0.070 |
Why?
| Lower Extremity | 1 | 2008 | 92 | 0.070 |
Why?
| Beverages | 1 | 2007 | 56 | 0.070 |
Why?
| Exercise Test | 2 | 2014 | 131 | 0.070 |
Why?
| Epinephrine | 2 | 1998 | 97 | 0.060 |
Why?
| Carbon Dioxide | 1 | 2006 | 95 | 0.060 |
Why?
| Microdialysis | 1 | 2005 | 19 | 0.060 |
Why?
| Intracellular Fluid | 1 | 2005 | 12 | 0.060 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 60 | 0.060 |
Why?
| Cell Respiration | 2 | 2016 | 41 | 0.060 |
Why?
| Creatine | 1 | 2004 | 38 | 0.060 |
Why?
| Fathers | 1 | 2024 | 23 | 0.060 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2005 | 326 | 0.060 |
Why?
| Skiing | 1 | 2004 | 3 | 0.060 |
Why?
| Endocrine System | 1 | 2004 | 16 | 0.060 |
Why?
| Immune System | 1 | 2004 | 43 | 0.060 |
Why?
| Sex Factors | 2 | 2004 | 712 | 0.060 |
Why?
| Rats, Zucker | 1 | 2023 | 68 | 0.050 |
Why?
| Caseins | 1 | 2023 | 78 | 0.050 |
Why?
| Eukaryotic Initiation Factor-2B | 1 | 2003 | 5 | 0.050 |
Why?
| Physical Education and Training | 1 | 2003 | 24 | 0.050 |
Why?
| Catecholamines | 2 | 2004 | 47 | 0.050 |
Why?
| Sports | 1 | 2003 | 40 | 0.050 |
Why?
| Infant, Newborn | 2 | 2020 | 2749 | 0.050 |
Why?
| Soybean Proteins | 1 | 2023 | 161 | 0.050 |
Why?
| Mothers | 1 | 2024 | 257 | 0.050 |
Why?
| Overweight | 1 | 2023 | 215 | 0.050 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2021 | 88 | 0.050 |
Why?
| Proteomics | 1 | 2023 | 314 | 0.050 |
Why?
| Hydralazine | 1 | 2000 | 4 | 0.040 |
Why?
| Body Fat Distribution | 1 | 2020 | 9 | 0.040 |
Why?
| Glycerol | 1 | 2000 | 15 | 0.040 |
Why?
| Polysomnography | 1 | 2020 | 71 | 0.040 |
Why?
| Osmolar Concentration | 2 | 2003 | 62 | 0.040 |
Why?
| Language | 1 | 2020 | 138 | 0.040 |
Why?
| Thiobarbituric Acid Reactive Substances | 1 | 1999 | 10 | 0.040 |
Why?
| Reactive Oxygen Species | 1 | 2021 | 409 | 0.040 |
Why?
| Plethysmography | 1 | 2019 | 43 | 0.040 |
Why?
| Insulin-Like Growth Factor I | 1 | 2019 | 136 | 0.040 |
Why?
| Sleep | 1 | 2020 | 181 | 0.040 |
Why?
| Feasibility Studies | 1 | 2020 | 390 | 0.040 |
Why?
| Bicycling | 1 | 1998 | 25 | 0.040 |
Why?
| Adrenergic beta-Agonists | 1 | 1998 | 43 | 0.040 |
Why?
| Community-Based Participatory Research | 1 | 2020 | 198 | 0.040 |
Why?
| Atenolol | 1 | 1998 | 13 | 0.040 |
Why?
| Xenon Radioisotopes | 1 | 1998 | 2 | 0.040 |
Why?
| Pilot Projects | 1 | 2020 | 698 | 0.040 |
Why?
| Carbon Radioisotopes | 1 | 1998 | 53 | 0.040 |
Why?
| Hemoglobins | 2 | 2009 | 109 | 0.040 |
Why?
| Lipoproteins | 1 | 2016 | 40 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 1808 | 0.030 |
Why?
| Mice, Inbred BALB C | 1 | 2016 | 296 | 0.030 |
Why?
| Neck | 1 | 2016 | 99 | 0.030 |
Why?
| Linear Models | 1 | 2016 | 279 | 0.030 |
Why?
| Isometric Contraction | 1 | 2014 | 21 | 0.030 |
Why?
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 17 | 0.030 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2014 | 49 | 0.030 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 50 | 0.030 |
Why?
| Torque | 1 | 2014 | 17 | 0.030 |
Why?
| Glucose Clamp Technique | 1 | 2014 | 15 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2016 | 583 | 0.030 |
Why?
| Calorimetry, Indirect | 1 | 2014 | 25 | 0.030 |
Why?
| Glucose Tolerance Test | 1 | 2014 | 58 | 0.030 |
Why?
| Basal Metabolism | 1 | 2014 | 32 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 93 | 0.030 |
Why?
| Demography | 1 | 2014 | 94 | 0.030 |
Why?
| Prognosis | 1 | 2019 | 1978 | 0.030 |
Why?
| Follow-Up Studies | 1 | 2019 | 2242 | 0.030 |
Why?
| Recovery of Function | 1 | 2014 | 191 | 0.030 |
Why?
| Survivors | 1 | 2014 | 128 | 0.030 |
Why?
| Radiopharmaceuticals | 1 | 2014 | 204 | 0.030 |
Why?
| Magnetic Resonance Imaging | 1 | 2020 | 1548 | 0.030 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2014 | 189 | 0.030 |
Why?
| Ambulatory Care | 1 | 2014 | 230 | 0.030 |
Why?
| Positron-Emission Tomography | 1 | 2014 | 292 | 0.030 |
Why?
| Leg | 2 | 2003 | 123 | 0.020 |
Why?
| Peroxisome Proliferator-Activated Receptors | 1 | 2012 | 14 | 0.020 |
Why?
| Hypolipidemic Agents | 1 | 2012 | 28 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2014 | 978 | 0.020 |
Why?
| Plasma Volume | 1 | 2009 | 4 | 0.020 |
Why?
| Capillary Permeability | 1 | 2009 | 34 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 1164 | 0.020 |
Why?
| Radial Artery | 1 | 2009 | 31 | 0.020 |
Why?
| Tissue Distribution | 1 | 2009 | 166 | 0.020 |
Why?
| Veins | 1 | 2009 | 73 | 0.020 |
Why?
| Population | 1 | 2007 | 9 | 0.020 |
Why?
| Cardiac Output | 1 | 2007 | 44 | 0.020 |
Why?
| Hormones | 1 | 2007 | 57 | 0.020 |
Why?
| Coloring Agents | 1 | 2007 | 66 | 0.020 |
Why?
| Palmitoylcarnitine | 1 | 2005 | 7 | 0.020 |
Why?
| Methods | 1 | 2005 | 55 | 0.020 |
Why?
| Reference Standards | 1 | 2005 | 52 | 0.020 |
Why?
| Sex Characteristics | 1 | 2007 | 198 | 0.020 |
Why?
| Body Weight | 1 | 2007 | 517 | 0.020 |
Why?
| Fluorocarbons | 1 | 2005 | 58 | 0.020 |
Why?
| Rabbits | 1 | 2005 | 372 | 0.010 |
Why?
| Granulocytes | 1 | 2004 | 26 | 0.010 |
Why?
| Albumins | 1 | 2004 | 31 | 0.010 |
Why?
| Task Performance and Analysis | 1 | 2004 | 51 | 0.010 |
Why?
| Blood Flow Velocity | 1 | 2002 | 99 | 0.010 |
Why?
| Valine | 1 | 2002 | 57 | 0.010 |
Why?
| Glycine | 1 | 2002 | 78 | 0.010 |
Why?
|
|
Borsheim's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|